Breaking News

Novo Nordisk CEO to Step Down

A search for Lars Fruergaard Jørgensen’s successor is ongoing.

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s successor is ongoing.

Novo Nordisk says the leadership transition is “made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024.”

Considering the recent market challenges, the share price decline, and wishes from the Novo Nordisk Foundation, the Novo Nordisk Board and Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders. Jørgensen has agreed to continue as CEO for a period to support a smooth transition to new leadership.

Jørgensen says: “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish. I am proud of the results I have helped create together with my leadership team, the Board, and the thousands of employees who work every day to drive change to defeat serious chronic diseases.”

More Novo Nordisk News

Earlier this week, Septerna Inc. and Novo Nordisk entered an exclusive global collaboration and license agreement to discover, develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters